Q1 Earnings Forecast for Solid Biosciences Issued By Wedbush

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities research analysts at Wedbush upped their Q1 2025 earnings estimates for shares of Solid Biosciences in a report issued on Wednesday, February 19th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.60) per share for the quarter, up from their previous estimate of ($0.77). Wedbush currently has a "Strong-Buy" rating on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. Wedbush also issued estimates for Solid Biosciences' Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($1.78) EPS, FY2027 earnings at ($1.79) EPS, FY2028 earnings at ($1.41) EPS and FY2029 earnings at ($0.55) EPS.

SLDB has been the subject of a number of other reports. Citizens Jmp upgraded shares of Solid Biosciences to a "strong-buy" rating in a research note on Tuesday, December 10th. Truist Financial started coverage on shares of Solid Biosciences in a report on Wednesday, January 8th. They issued a "buy" rating and a $16.00 target price on the stock. JMP Securities assumed coverage on shares of Solid Biosciences in a report on Tuesday, December 10th. They set an "outperform" rating and a $15.00 price objective on the stock. Chardan Capital upped their target price on shares of Solid Biosciences from $15.00 to $16.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, HC Wainwright reissued a "buy" rating and set a $16.00 target price on shares of Solid Biosciences in a research note on Friday, January 10th. Nine analysts have rated the stock with a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, Solid Biosciences has an average rating of "Buy" and an average target price of $15.40.

Solid Biosciences Stock Down 3.7 %

Shares of Solid Biosciences stock traded down $0.22 during trading on Friday, hitting $5.78. The stock had a trading volume of 2,182,549 shares, compared to its average volume of 3,437,005. The stock has a 50 day simple moving average of $3.83 and a 200 day simple moving average of $5.76. The company has a market capitalization of $234.55 million, a PE ratio of -1.90 and a beta of 2.01. Solid Biosciences has a 1 year low of $2.88 and a 1 year high of $15.05.

Institutional Investors Weigh In On Solid Biosciences

Institutional investors have recently made changes to their positions in the stock. Quantum Private Wealth LLC purchased a new stake in shares of Solid Biosciences in the third quarter worth $220,000. Los Angeles Capital Management LLC purchased a new stake in shares of Solid Biosciences in the third quarter worth $293,000. Valence8 US LP purchased a new stake in shares of Solid Biosciences in the third quarter worth $110,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Solid Biosciences in the third quarter worth $71,000. Finally, FMR LLC purchased a new stake in shares of Solid Biosciences in the third quarter worth $305,000. Hedge funds and other institutional investors own 81.46% of the company's stock.

Insider Activity at Solid Biosciences

In other Solid Biosciences news, insider Jessie Hanrahan sold 4,610 shares of the stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total transaction of $25,816.00. Following the sale, the insider now owns 14,235 shares in the company, valued at $79,716. This represents a 24.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO David T. Howton sold 5,072 shares of the stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total value of $28,403.20. Following the sale, the chief operating officer now owns 15,663 shares in the company, valued at approximately $87,712.80. This represents a 24.46 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,069 shares of company stock worth $137,301. Insiders own 13.63% of the company's stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.